Background: Apoptosis is a necessary process to control cell numbers in multicellular organisms. In many chronic inflammatory diseases, reduced cell death of different types of granulocytes is one important mechanism for cell accumulation. Here, we studied the role of caspases in neutrophil and eosinophil apoptosis in the presence or absence of granulocyte-macrophage stimulating factor and anti-CD95 monoclonal antibodies, respectively. Methods: Granulocytes were isolated from human blood using standard protocols. Immunoblot and functional studies with cell-permeable specific peptide inhibitors were performed to analyze caspase involvement. Fas receptor and Fas ligand expression was analyzed by RT-PCR, flow cytometry, and immunoblotting. Cell death was analyzed by ethidium bromide exclusion test. Results: Caspases 3 and 8 are critically involved in the regulation of neutrophil apoptosis in vitro. In contrast, these two caspases did not appear to play a major role in the regulation of eosinophil apoptosis. However, the broad-range caspase inhibitor VAD prevented eosinophil death, indicating that caspases are also involved within the apoptotic machinery of eosinophils. Functional inhibitor studies suggested that caspase 9 is crucial for both caspase 3 and 8 activation, at least in neutrophils. In contrast, spontaneous apoptosis of neutrophils or eosinophils is unlikely to be the consequence of Fas ligand/Fas receptor molecular interactions. Conclusion: The data of this study indicate differences in the usage of caspases between neutrophils and eosinophils.

Martin S, Green D: Protease activation during apoptosis: Death by a thousand cuts. Cell 1995;82:349–352.
Henkart PA: ICE family protease: Mediators of all apoptotic cell death? Immunity 1996;4:195–201.
Hu S, Snipas SJ, Vincenz C, Salvesen G, Dixit VM: Caspase-14 is a novel developmentally regulated protease. J Biol Chem 1998;273:29648–29653.
Casciola-Rosen L, Nicholson DW, Chong T, Rowan KR, Thornberry NA, Miller DK, Rosen A: Apopain/CPP32 cleaves proteins that are essential for cellular repair: A fundamental principle of apoptotic death. J Exp Med 1996;183:1957–1964.
Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998;391:43–50.
Sakahira H, Enari M, Nagata S: Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998;391:96–99.
Wolf BB, Green DR: Suicidal tendencies: Apoptotic cell death by caspase family proteinases. J Biol Chem 1999;274:20049–20052.
Yousefi S, Green DR, Blaser K, Simon HU: Protein-tyrosine phosphorylation regulates apoptosis in human eosinophils and neutrophils. Proc Natl Acad Sci USA 1994;91:10868–10872.
Yousefi S, Hoessli DC, Blaser K, Mills GB, Simon HU: Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J Exp Med 1996;183:1407–1414.
Simon HU, Yousefi S, Dibbert B, Levi-Schaffer F, Blaser K: Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils. Eur J Immunol 1997;27:3536–3539.
Dibbert B, Daigle I, Braun D, Schranz C, Weber M, Blaser K, Zangemeister-Wittke U, Akbar AN, Simon HU: Role of bcl-xL in delayed eosinophil apoptosis mediated by granulocyte-macrophage colony-stimulating factor and interleukin-5. Blood 1998;92:778–783.
Dibbert B, Weber M, Nikolaizik W, Vogt P, Schöni MH, Blaser K, Simon HU: Cytokine-mediated bax deficiency and consequent delayed neutrophil apoptosis: A general mechanism to accumulate effector cells in inflammation. Proc Natl Acad Sci USA 1999;96:13330–13335.
Hebestreit H, Yousefi S, Balatti I, Weber M, Crameri R, Simon D, Hartung K, Schapowal A, Blaser K, Simon HU: Expression and function of the Fas receptor on human blood and tissue eosinophils. Eur J Immunol 1996;26:1775–1780.
Iwai K, Miyawaki T, Takizawa T, Konno A, Ohta K, Yachie A, Seki H, Taniguchi N: Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes, and neutrophils. Blood 1994;84:1201–1208.
Liles WK, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ: Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils. J Exp Med 1996;184:429–440.
Murray J, Barbara JAJ, Dunkley SA, Lopez AF, Van Ostade X, Condliffe AM, Dransfield I, Haslett C, Chilvers ER: Regulation of neutrophil apoptosis by tumor necrosis factor-α: Requirement for TNFR55 and TNFR75 for induction of apoptosis in vitro. Blood 1997;90:2772–2783.
Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K: Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 1997;158:3902–3908.
Grigg J, Savill J, Sarraf C, Haslett C, Silverman M: Neutrophil apoptosis and clearance from neonatal lung. Lancet 1991;338:720–722.
Pongracz J, Webb P, Wang K, Deacon E, Lunn O, Lord JM: Spontaneous neutrophil apoptosis involves caspase 3-mediated activation of protein kinase C-δ. J Biol Chem 1999;274:37329–37334.
Khwaja A, Tatton L: Caspase-mediated proteolysis and activation of protein kinase Cδ plays a central role in neutrophil apoptosis. Blood 1999;94:291–301.
Simon HU, Yousefi S, Dommann-Scherrer CC, Zimmermann DR, Bauer S, Barandun J, Blaser K: Expansion of cytokine-producing CD4CD8 T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med 1996;183:1071–1082.
Herr I, Balemans L, Böhler T, Walczak H, Debatin KM: Monitoring of CD95 (APO-1/Fas) ligand expression in human T cells by quantitative RT-PCR. Cell Death Differ 1996;3:299–305.
Fernandes-Alnemri T, Litwack G, Alnemri ES: CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1β converting enzyme. J Biol Chem 1994;269:30761–30764.
Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju AM, Smulson ME, Yamin TT, Yu VL, Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 1995;376:37–43.
Muzio M, Chinnaiyan AM, Kischkel FC, O’Rourke K, Shevchenko FC, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R, Mann M, Krammer PH, Peter ME, Dixit VM: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/Apo-1) death-inducing signaling complex. Cell 1996;85:817–827.
Simon HU, Yousefi S, Dibbert B, Hebestreit H, Weber M, Branch DR, Blaser K, Levi-Schaffer F, Anderson GP: Role for tyrosine phosphorylation and Lyn tyrosine kinase in Fas receptor-mediated apoptosis in eosinophils. Blood 1998;92:547–557.
Hebestreit H, Dibbert B, Balatti I, Braun D, Schapowal A, Blaser K, Simon HU: Disruption of Fas receptor signaling by nitric oxide in eosinophils. J Exp Med 1998;187:415–425.
McGowan EB, Becker E, Detwiler TC: Inhibition of calpain in intact platelets by the thiol protease inhibitor E-64d. Biochem Biophys Res Commun 1989;158:432–435.
Yang Y, Liu ZH, Ware CF, Ashwell JD: A cystein protease inhibitor prevents activation-induced T-cell apoptosis and death of peripheral blood cells from human immunodeficiency virus-infected individuals by inhibiting upregulation of Fas ligand. Blood 1997;89:550–557.
Dhein J, Walczak H, Bäumler C, Debatin KM, Krammer PH: Autocrine T-cell suicide mediated by APO-1/CD95. Nature 1995;373:438–441.
Peter ME, Dhein J, Ehret A, Hellbardt S, Walczak H, Moldenhauer G, Krammer PH: APO-1 (CD95)-dependent and -independent antigen receptor-induced apoptosis in human T and B cell lines. Int Immunol 1995;7:1873–1877.
Hahne K, Rimoldi D, Schröter M, Romero P, Schreier M, French LE, Schneider P, Bornand T, Fontana A, Lienard D, Cerottini JC, Tschopp J: Melanoma cell expression of Fas (APO-1/CD95) ligand: Implications for tumor immune escape. Science 1996;274:1363–1366.
Mannick JB, Hausladen A, Liu L, Hess DT, Zeng M, Miao QX, Kane LS, Gow AJ, Stamler J: Fas-induced caspase denitrosylation. Science 1999;284:651–654.
Cardone MH, Roy N, Stennicke H, Salvesen GS, Frabke TF, Stanbridge E, Frisch S, Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318–1321.
Talanian RV, Quinlan C, Trautz S, Hackett MC, Mankovich JA, Banach D, Ghayur T, Brady KD, Wong WW: Substrate specificities of caspase family proteases. J Biol Chem 1997;272:9677–9682.
Smith D, Sieg S, Kaplan D: Aberrant detection of cell surface Fas ligand with anti-peptide antibodies. J Immunol 1998;160:4159–4160.
Brown SB, Savill J: Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol 1999;162:480–485.
Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H: Metalloproteinase-mediated release of human Fas ligand. J Exp Med 1995;182:1777–1783.
Allison J, Georgiou HM, Strasser A, Vaux DL: Transgenic expression of CD95 ligand on islet β cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997;94:3943–3947.
Desbarats J, Duke RC, Newell MK: Newly discovered role for Fas ligand in the cell-cycle arrest of CD4+ T cells. Nat Med 1998;4:1377–1382.
Daigle I, Rückert B, Schnetzler G, Simon HU: Induction of the IL-10 gene via the Fas receptor in monocytes – An anti-inflammatory mechanism in the absence of apoptosis. Eur J Immunol 2000;30:2991–2997.
Kuwana T, Smith JJ, Muzio M, Dixit V, Newmeyer DD, Kornbluth S: Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c. J Biol Chem 1998;273:16589–16594.
Cheng EHY, Kirsch DG, Clem RJ, Ravi R, Kastan MB, Bedi A, Ueno K, Hardwick JM: Conversion of bcl-2 to bax-like death effector by caspases. Science 1997;278:1966–1968.
Kirsch DG, Doseff A, Chau BN, Lim DS, de Souza-Pinto NC, Hansford R, Kastan MB, Lazebnik YA, Hardwick JM: Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol Chem 1999;274:21155–21161.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.